L01EX01 - Suchergebnisse

Europäische Union - Deutsch - EMA (European Medicines Agency)

sutent

pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastische mittel - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

sutent 12.5 mg hartkapseln

pfizer ag - sunitinibum - hartkapseln - sunitinibum 12.5 mg ut sunitinibi malas, mannitolum, carmellosum natricum conexum, povidonum k 25, magnesii stearas, kapselhülle: gelatina, e 172 (rubrum), e 171, drucktinte: lacca, propylenglycolum, natrii hydroxidum, povidonum, e 171, pro capsula corresp. natrium 0.47 mg. - behandlung von gastrointestinalen stromatumoren, behandlung des nierenzellkarzinoms, behandlung von neuroendokrinem pankreaskarzinom - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

sutent 25 mg hartkapseln

pfizer ag - sunitinibum - hartkapseln - sunitinibum 25 mg ut sunitinibi malas, mannitolum, carmellosum natricum conexum, povidonum k 25, magnesii stearas, kapselhülle: gelatina, e 172 (rubrum), e 171, e 172 (flavum), e 172 (nigrum), drucktinte: lacca, propylenglycolum, natrii hydroxidum, povidonum, e 171, pro capsula corresp. natrium 0.36 mg. - behandlung von gastrointestinalen stromatumoren, behandlung des nierenzellkarzinoms, behandlung von neuroendokrinem pankreaskarzinom - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

sutent 50 mg hartkapseln

pfizer ag - sunitinibum - hartkapseln - sunitinibum 50 mg ut sunitinibi malas, mannitolum, carmellosum natricum conexum, povidonum k 25, magnesii stearas, kapselhülle: gelatina, e 172 (rubrum), e 171, e 172 (flavum), e 172 (nigrum), drucktinte: lacca, propylenglycolum, natrii hydroxidum, povidonum, e 171, pro capsula corresp. natrium 0.71 mg. - behandlung von gastrointestinalen stromatumoren, behandlung des nierenzellkarzinoms, behandlung von neuroendokrinem pankreaskarzinom - synthetika